EGFR and neoplasm: It binds to cysteine residues near the kinase domain, thereby inducing cell death in tumor cells expressing EGFR.152,153 In May 2016, it was approved for marketing in Korea for the treatment of patients with locally advanced or metastatic NSCLC that is positive for the EGFRT790M mutation.